IMA
ImageneBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
IMG-007 has shown tolerability across more than 150 exposed subjects, management says ADAPTIVE is enrolling to plan, and the company now has additional financing support, so a clean 2027 readout could re-rate a stock still trading at a depressed small-cap biotech valuation [#10-K-2026-03-10].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Broad rather than near-dated catalyst calendar, with core topline only guided for 2027.
Momentum
58
Value
57
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.80
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $16.00
Why
Momentum58 · Δ7d -
Value57 · Δ7d 0.0
Sentiment43 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
58
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.3
Sentiment
43
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 58.4 / Value 57.1 / Sentiment 42.7
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$64.36M
Beta
0.44
Shares Out
21.83M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.32
Rev YoY
-100.0%
EPS YoY
-18.1%
Gross Margin
-
Op Margin
-10373.9%
Net Debt
-$124.39M
Current Ratio
13.24
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology